Your browser doesn't support javascript.
loading
Ordered and deterministic cancer genome evolution after p53 loss.
Baslan, Timour; Morris, John P; Zhao, Zhen; Reyes, Jose; Ho, Yu-Jui; Tsanov, Kaloyan M; Bermeo, Jonathan; Tian, Sha; Zhang, Sean; Askan, Gokce; Yavas, Aslihan; Lecomte, Nicolas; Erakky, Amanda; Varghese, Anna M; Zhang, Amy; Kendall, Jude; Ghiban, Elena; Chorbadjiev, Lubomir; Wu, Jie; Dimitrova, Nevenka; Chadalavada, Kalyani; Nanjangud, Gouri J; Bandlamudi, Chaitanya; Gong, Yixiao; Donoghue, Mark T A; Socci, Nicholas D; Krasnitz, Alex; Notta, Faiyaz; Leach, Steve D; Iacobuzio-Donahue, Christine A; Lowe, Scott W.
Afiliação
  • Baslan T; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Morris JP; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhao Z; Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
  • Reyes J; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ho YJ; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tsanov KM; Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Bermeo J; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tian S; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhang S; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Askan G; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yavas A; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lecomte N; Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Erakky A; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Varghese AM; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhang A; Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kendall J; Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ghiban E; Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chorbadjiev L; Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wu J; Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Dimitrova N; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chadalavada K; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
  • Nanjangud GJ; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
  • Bandlamudi C; Technical School of Electronic Systems, Technical University of Sofia, Sofia, Bulgaria.
  • Gong Y; Phillips Research North America, Oncology Informatics and Genomics, Cambridge, MA, USA.
  • Donoghue MTA; Phillips Research North America, Oncology Informatics and Genomics, Cambridge, MA, USA.
  • Socci ND; Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Krasnitz A; Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Notta F; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Leach SD; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Iacobuzio-Donahue CA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lowe SW; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature ; 608(7924): 795-802, 2022 08.
Article em En | MEDLINE | ID: mdl-35978189
ABSTRACT
Although p53 inactivation promotes genomic instability1 and presents a route to malignancy for more than half of all human cancers2,3, the patterns through which heterogenous TP53 (encoding human p53) mutant genomes emerge and influence tumorigenesis remain poorly understood. Here, in a mouse model of pancreatic ductal adenocarcinoma that reports sporadic p53 loss of heterozygosity before cancer onset, we find that malignant properties enabled by p53 inactivation are acquired through a predictable pattern of genome evolution. Single-cell sequencing and in situ genotyping of cells from the point of p53 inactivation through progression to frank cancer reveal that this deterministic behaviour involves four sequential phases-Trp53 (encoding mouse p53) loss of heterozygosity, accumulation of deletions, genome doubling, and the emergence of gains and amplifications-each associated with specific histological stages across the premalignant and malignant spectrum. Despite rampant heterogeneity, the deletion events that follow p53 inactivation target functionally relevant pathways that can shape genomic evolution and remain fixed as homogenous events in diverse malignant populations. Thus, loss of p53-the 'guardian of the genome'-is not merely a gateway to genetic chaos but, rather, can enable deterministic patterns of genome evolution that may point to new strategies for the treatment of TP53-mutant tumours.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Genes p53 / Proteína Supressora de Tumor p53 / Genoma / Progressão da Doença / Perda de Heterozigosidade / Carcinogênese Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nature Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Genes p53 / Proteína Supressora de Tumor p53 / Genoma / Progressão da Doença / Perda de Heterozigosidade / Carcinogênese Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nature Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos